Overall And Progression Free Survival From The Mcrn-003/Myx.1 Trial: A Single Arm Phase Ii Study Of High-Dose Weekly Carfilzomib Plus Cyclophosphamide And Dexamethasone In The Treatment Of Relapsed Multiple Myeloma

Background: Carfilzomib is effective in the treatment of relapsed and refractory multiple myeloma (RRMM). Questions remain regarding optimal dosing strategies and combinations. The MCRN-003/MYX.1 single arm phase II clinical trial of high-dose once weekly carfilzomib in combination with dexamethasone and cyclophosphamide (wCCD) in RRMM met its primary endpoint with an overall response rate (ORR) ≥ 80% after 4 treatment cycles [Venner, Blood 2018 132:1984]. This abstract focuses on previously unreported protocol specified secondary and exploratory endpoints including progression free (PFS) and overall survival (OS).